Skip to content

Early Prediction of Post-Stroke Depression: A Prospective Cohort Study Investigating Multidimensional Biomarkers Along the IL-6/STAT3/BBB Pathway

Early Prediction of Post-Stroke Depression: A Prospective Cohort Study Investigating Multidimensional Biomarkers Along the IL-6/STAT3/BBB Pathway

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127022
Enrollment
Unknown
Registered
2026-06-23
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Case series:Not applicable

Sponsors

The Second Affiliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years. 2. First-ever acute ischemic stroke, diagnosed according to the criteria of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke, and confirmed by cranial CT or MRI. 3. Time from stroke onset to hospital admission <= 72 hours. 4. Good pre-stroke functional status (modified Rankin Scale score mRS <= 1). 5. The patient or their legally authorized representative fully understands the study and provides written informed consent.

Exclusion criteria

Exclusion criteria: 1. Intracerebral hemorrhage, subarachnoid hemorrhage, transient ischemic attack (TIA), or other non-ischemic cerebrovascular diseases; 2. A definite diagnosis of major psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, anxiety disorder) before stroke, or current use of related psychotropic medications; 3. Presence of severe infection (e.g., body temperature >38.0°C, or procalcitonin [PCT] >0.5 ng/mL), malignant tumor, severe liver or kidney dysfunction, or autoimmune disease requiring immunosuppressive therapy at the time of admission; 4. Severe aphasia, impaired consciousness, or cognitive impairment that, in the investigator's judgment, precludes completion of depression rating scales; 5. Expected survival of less than 6 months; 6. Current participation in another clinical trial that may affect the results of this study.

Design outcomes

Primary

MeasureTime frame
IL-6;p-STAT3;S100B;Single nucleotide polymorphism, SNP;

Countries

China

Contacts

Public ContactShi Hongting

The Second Affiliated Hospital of Guangzhou Medical University

317564816@qq.com+86 134 1612 6065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026